Form 4: Ginkgo Bioworks CFO Mark Dmytruk Reports Stock Transactions

Mark Dmytruk, CFO of Ginkgo Bioworks Holdings, Inc., reports the acquisition and disposal of Class A and Class B Common Stock, as well as Restricted Stock Units, through various transactions including vesting and sales to cover tax obligations.

Summary

• On September 11 and 12, 2024, Mark Dmytruk, the CFO of Ginkgo Bioworks Holdings, Inc., engaged in multiple transactions involving the company's stock.
• These transactions included the acquisition of Class A Common Stock through the vesting of Restricted Stock Units (RSUs) and the conversion of Class B Common Stock to Class A Common Stock.
• Dmytruk also disposed of Class A Common Stock to cover tax withholding obligations related to the vesting of RSUs.
• Specifically, on September 11, 2024, 1,634, 453, and 572 shares of Class A Common Stock were acquired through RSU vesting.
• Additionally, 34 shares of Class A Common Stock were acquired through the conversion of Class B Common Stock.
• On September 12, 2024, 1,148 shares of Class A Common Stock were sold at a price of $6.172 per share to cover tax obligations.
• Following these transactions, Dmytruk beneficially owns 28,749 shares of Class A Common Stock, 15,509 shares of Class B Common Stock, 9,632 RSUs vesting from April 1, 2023, 13,594 RSUs vesting from April 1, 2024, and 24,064 RSUs vesting from April 1, 2024.
• The reported transactions were executed pursuant to the terms of Ginkgo Bioworks' equity incentive plans, which allow for 'sell to cover' transactions to satisfy tax withholding obligations.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting routine stock transactions. The vesting of RSUs is a positive sign, but the sale of shares to cover taxes is a neutral event. Overall, the sentiment is slightly positive due to the vesting activity.

Positives

• The vesting of RSUs indicates that Dmytruk is meeting performance or time-based milestones set by the company.
• The conversion of Class B Common Stock to Class A Common Stock suggests confidence in the company's future performance.

Negatives

• The sale of shares to cover tax obligations, while routine, could be perceived negatively if investors interpret it as a lack of confidence in the company's future prospects, although the document states that these sales do not represent discretionary trades.

Risks

• The 'sell to cover' transactions could exert downward pressure on the stock price, albeit likely minimal given the relatively small volume.
• Investor sentiment could be negatively impacted if such transactions are perceived as a lack of confidence by company insiders, despite the explanation provided.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are a routine part of corporate governance and provide transparency into the transactions of company insiders. The transactions reported are typical for executives who receive stock-based compensation.

Comparison to Industry Standards

• Stock transactions by executives are common across publicly traded companies, particularly in the biotechnology sector where stock options and RSUs are frequently used as compensation.
• Companies like Amyris and Zymergen, which operate in similar synthetic biology spaces, also see regular Form 4 filings from their executives.
• The 'sell to cover' practice is a standard method for employees to manage tax obligations related to equity compensation, aligning with practices observed at companies like Intellia Therapeutics and CRISPR Therapeutics.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for slight price fluctuations from the sale of shares.
• Employees holding RSUs may be interested in the vesting schedules and tax implications of their equity compensation.

Key Dates